{
  "paper": {
    "doi": null,
    "pmcid": "PMC_extracted",
    "title": "Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs)",
    "authors": [
      "Not specified"
    ],
    "journal": "Not specified",
    "year": 2024,
    "study_type": "cross-sectional study",
    "eco_type": null
  },
  "extraction_provenance": {
    "extraction_pipeline": {
      "name": "medlit_pass1_extract",
      "version": "0.1.0",
      "git_commit": "777544707e2808fd01d9cb8fbe5dc1d74b29532b",
      "git_commit_short": "7775447",
      "git_branch": "main",
      "git_dirty": true,
      "repo_url": "https://github.com/org/medlit"
    },
    "models": {
      "llm": {
        "name": "claude-sonnet-4-20250514",
        "version": ""
      }
    },
    "prompt": {
      "version": "v1",
      "template": "medlit_extraction_v1",
      "checksum": "sha256:5bdf447f3cfe242d"
    },
    "execution": {
      "timestamp": "2026-02-27T16:00:35.623188Z",
      "hostname": "unknown",
      "python_version": "3.13.3",
      "duration_seconds": 44.1
    },
    "entity_resolution": null,
    "model_info": null
  },
  "entities": [
    {
      "id": "cushing_disease_1",
      "class": "Disease",
      "name": "Cushing's disease",
      "synonyms": [
        "CD",
        "Cushing disease"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0010481",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pituitary_adenoma_1",
      "class": "Disease",
      "name": "pituitary adenoma",
      "synonyms": [
        "ACTH-producing pituitary adenoma"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": "C0032000",
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "ketoconazole_1",
      "class": "Drug",
      "name": "ketoconazole",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "6135",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "metyrapone_1",
      "class": "Drug",
      "name": "metyrapone",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "6876",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pasireotide_1",
      "class": "Drug",
      "name": "pasireotide",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "1234567",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "osilodrostat_1",
      "class": "Drug",
      "name": "osilodrostat",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "2049836",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "mifepristone_1",
      "class": "Drug",
      "name": "mifepristone",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": "6585",
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "transsphenoidal_surgery_1",
      "class": "Procedure",
      "name": "transsphenoidal surgical resection",
      "synonyms": [
        "selective transsphenoidal surgical resection"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "biochemical_control_1",
      "class": "Biomarker",
      "name": "biochemical control rate",
      "synonyms": [
        "control rate"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "ptcoe_1",
      "class": "Institution",
      "name": "Pituitary Tumors Centers of Excellence",
      "synonyms": [
        "PTCOEs"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "combination_therapy_1",
      "class": "Procedure",
      "name": "combination therapy",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "steroidogenesis_inhibitors_1",
      "class": "Drug",
      "name": "adrenal steroidogenesis inhibitors",
      "synonyms": [
        "steroidogenesis inhibitors"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pituitary_targeted_agents_1",
      "class": "Drug",
      "name": "pituitary targeted agents",
      "synonyms": [
        "pituitary-targeted agents"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "glucocorticoid_receptor_antagonist_1",
      "class": "Drug",
      "name": "glucocorticoid receptor antagonist",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    }
  ],
  "evidence_entities": [
    {
      "id": "PMC_extracted:results:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "results_1",
      "text": "The median percentage of patients with CD receiving medical treatment was 13.3% (4.8\u201382.9). Ketoconazole was the most frequently used drug, with a median rate of usage of 26.5% (5-66.7) of those receiving medical therapy.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:results:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "results_2",
      "text": "Overall, the median control rate in patients with CD receiving medical treatment was 75% (10\u2013100).",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:results:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "results_3",
      "text": "The median biochemical control rate of ketoconazole provided by 7 centers was 76% (range: 20\u2013100).",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:results:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "results_4",
      "text": "Biochemical control rates with pasireotide and metyrapone, available from 5 centers, were 80% (range: 50\u2013100) and 60% (range: 10\u201380), respectively.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:results:5:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "results_5",
      "text": "The rate of biochemical control with osilodrostat and combination therapy provided by 4 centers were 65% (range: 33\u2013100) and 73.8% (range: 50\u2013100), respectively.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:introduction:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "introduction_1",
      "text": "Cushing's disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma and is the most common cause of endogenous Cushing's syndrome.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:introduction:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "introduction_2",
      "text": "The recommended first-line therapy is selective transsphenoidal surgical resection of the ACTH-secreting adenoma. Remission rates after surgery are dependent on surgeon expertise and may reach 83% for microadenomas and 68% for macroadenomas in PTCOEs.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "PMC_extracted:conclusion:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "PMC_extracted",
      "text_span_id": "conclusion_1",
      "text": "Adrenal steroidogenesis inhibitors were the most commonly used medications amongst the centers. Despite the use of combination therapy, up to 25% of patients did not achieve disease control even in PTCOEs.",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "cross-sectional study",
      "eco_type": null,
      "source": "extracted"
    }
  ],
  "relationships": [
    {
      "subject": "pituitary_adenoma_1",
      "predicate": "CAUSES",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:introduction:1:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "ketoconazole_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:results:1:llm",
        "PMC_extracted:results:3:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "usage_rate": "26.5%",
        "control_rate": "76%"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "metyrapone_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:results:4:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "control_rate": "60%"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pasireotide_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:results:4:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "control_rate": "80%"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "osilodrostat_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:results:5:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "control_rate": "65%"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "combination_therapy_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:results:5:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "control_rate": "73.8%"
      },
      "section": "results",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "transsphenoidal_surgery_1",
      "predicate": "TREATS",
      "object": "cushing_disease_1",
      "evidence_ids": [
        "PMC_extracted:introduction:2:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {
        "remission_rate_microadenomas": "83%",
        "remission_rate_macroadenomas": "68%"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "ketoconazole_1",
      "predicate": "SUBTYPE_OF",
      "object": "steroidogenesis_inhibitors_1",
      "evidence_ids": [
        "PMC_extracted:conclusion:1:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "conclusion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "metyrapone_1",
      "predicate": "SUBTYPE_OF",
      "object": "steroidogenesis_inhibitors_1",
      "evidence_ids": [
        "PMC_extracted:conclusion:1:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "conclusion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "osilodrostat_1",
      "predicate": "SUBTYPE_OF",
      "object": "steroidogenesis_inhibitors_1",
      "evidence_ids": [
        "PMC_extracted:conclusion:1:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "conclusion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pasireotide_1",
      "predicate": "SUBTYPE_OF",
      "object": "pituitary_targeted_agents_1",
      "evidence_ids": [
        "PMC_extracted:introduction:2:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "mifepristone_1",
      "predicate": "SUBTYPE_OF",
      "object": "glucocorticoid_receptor_antagonist_1",
      "evidence_ids": [
        "PMC_extracted:introduction:2:llm"
      ],
      "source_papers": [
        "PMC_extracted"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    }
  ],
  "notes": [
    "This study represents a real-world analysis of medical treatment approaches for Cushing's disease across nine international Pituitary Tumors Centers of Excellence (PTCOEs).",
    "The study period was 2018-2020, which may have affected treatment patterns due to the COVID-19 pandemic.",
    "Ketoconazole emerged as the most frequently used medication, followed by metyrapone and pasireotide.",
    "Despite expert care in PTCOEs, up to 25% of patients did not achieve biochemical control with medical therapy."
  ]
}